These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 1780765

  • 1. A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment.
    Aledort LM.
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):1-2. PubMed ID: 1780765
    [No Abstract] [Full Text] [Related]

  • 2. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A.
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Considerations governing factor IX product choice in hemophilia B.
    Bray GL, Aledort LM.
    Transfusion; 1994 Jun; 34(6):554-5. PubMed ID: 8023402
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preclinical studies of a monoclonal antibody-purified factor IX, Mononine.
    Hrinda ME, Huang C, Tarr GC, Weeks R, Feldman F, Schreiber AB.
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):6-14. PubMed ID: 1780768
    [No Abstract] [Full Text] [Related]

  • 12. Clinical evaluation of recombinant factor IX.
    White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K, Courter S.
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [Abstract] [Full Text] [Related]

  • 13. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y, Boyeldieu D, Stieltjes N.
    Nouv Rev Fr Hematol (1978); 1994 Apr; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K, Hirose S, Taguchi H, Miyoshi I.
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical use of factor IX concentrates].
    Nyman D.
    Schweiz Med Wochenschr; 1975 Sep 13; 105(37):1188-90. PubMed ID: 1215901
    [Abstract] [Full Text] [Related]

  • 20. [The treatment of inherited coagulation disorders].
    Blombäck M, Nilsson IM.
    Lakartidningen; 1972 Dec 27; 69():Suppl 4:76-84. PubMed ID: 4540328
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.